Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and Respiratory Tract Infections

fingolimod hydrochloride has been researched along with Respiratory Tract Infections in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Becker, KA; Edwards, MJ; Futerman, AH; Grassmé, H; Gulbins, E; Japtok, L; Joseph, T; Kleuser, B; Lang, S; Lentsch, AB; Pewzner-Jung, Y; Schuchman, EH; Steinmann, J; Tavakoli Tabazavareh, S; Tuemmler, B1
Antel, J; Comi, G; Haas, T; Kappos, L; Karlsson, G; Korn, AA; Montalban, X; O'Connor, P; Polman, CH; Radue, EW1

Trials

1 trial(s) available for fingolimod hydrochloride and Respiratory Tract Infections

ArticleYear
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adolescent; Adult; Brain; Brain Diseases; Double-Blind Method; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Respiratory Tract Infections; Sphingosine; Statistics, Nonparametric

2006

Other Studies

1 other study(ies) available for fingolimod hydrochloride and Respiratory Tract Infections

ArticleYear
Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa.
    EMBO molecular medicine, 2014, Volume: 6, Issue:9

    Topics: Acid Ceramidase; Administration, Inhalation; Animals; Ceramides; Cystic Fibrosis; Disease Susceptibility; Fingolimod Hydrochloride; Humans; Mice, Inbred C57BL; Mice, Transgenic; Propylene Glycols; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sphingosine; Trachea

2014